DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-394/S-008

Boehringer Ingelheim
900 Ridgebury Rd/P.O.Box 368
Ridgefield, CT 06877-0368

Dear Ms. Billingham:

Please refer to your supplemental new drug application dated, June 1, 2007, received June 4, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Atrovent (ipratropium bromide) Nasal Spray.

We acknowledge receipt of your submissions dated, November 28, and December 4, 2007 and April 8, 2008. The April 8, 2008, submission constitutes a complete response to our December 4, 2007, action letter.

This "Changes Being Effected" supplemental new drug application provide(s) for Atrovent (ipratropium bromide) provides for revisions to the animal to human exposure ratios in Carcinogenesis, Mutagenesis, and Impairment of Fertility and Overdosage sections.

We have completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at http://www.fda.gov/oc/datacouncil/spl.html that is identical to the submitted labeling (package insert and patient instructions for use submitted April 8, 2008). Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved NDA 20-394/S-008."

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Angela Robinson, Regulatory Project Manager, at (301) 796-2284.

Sincerely,

Badrul A. Chowdhury, M.D., Ph.D.
Director
Division of Pulmonary and Allergy Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Badrul Chowdhury
10/14/2008 10:18:16 AM